Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume 29, Issue 6, Pages 1379-1388
Publisher
Springer Science and Business Media LLC
Online
2023-05-16
DOI
10.1038/s41591-023-02363-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma
- (2023) Francesca Del Bufalo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Shared and distinct biological circuits in effector, memory and exhausted CD8+ T cells revealed by temporal single-cell transcriptomics and epigenetics
- (2022) Josephine R. Giles et al. NATURE IMMUNOLOGY
- Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy
- (2022) Amy N. Courtney et al. BLOOD
- LEF1 Drives a Central Memory Program and Supports Antitumor Activity of Natural Killer T Cells
- (2022) Ho Ngai et al. Cancer Immunology Research
- Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032
- (2021) Alice L. Yu et al. CLINICAL CANCER RESEARCH
- Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
- (2021) Evan W. Weber et al. SCIENCE
- Integrated analysis of multimodal single-cell data
- (2021) Yuhan Hao et al. CELL
- An NK-like CAR T cell transition in CAR T cell dysfunction
- (2021) Charly R. Good et al. CELL
- Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma
- (2021) Amani Makkouk et al. Journal for ImmunoTherapy of Cancer
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
- (2020) Enli Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glypican-3–Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma
- (2020) Sai Arun Batra et al. Cancer Immunology Research
- mRNA destabilization by BTG1 and BTG2 maintains T cell quiescence
- (2020) Soo Seok Hwang et al. SCIENCE
- Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis
- (2020) Andras Heczey et al. NATURE MEDICINE
- Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma
- (2020) Karin Straathof et al. Science Translational Medicine
- The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
- (2019) Katrin Mestermann et al. Science Translational Medicine
- NKT cells co-expressing a GD2-specific chimeric antigen receptor and IL-15 show enhanced in vivo persistence and antitumor activity against neuroblastoma
- (2019) Xin Xu et al. CLINICAL CANCER RESEARCH
- Clinical lessons learned from the first leg of the CAR T cell journey
- (2019) Robbie G. Majzner et al. NATURE MEDICINE
- Fast, sensitive and accurate integration of single-cell data with Harmony
- (2019) Ilya Korsunsky et al. NATURE METHODS
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bimodal CD40/Fas-Dependent Crosstalk between iNKT Cells and Tumor-Associated Macrophages Impairs Prostate Cancer Progression
- (2018) Filippo Cortesi et al. Cell Reports
- IL-21 Selectively Protects CD62L+NKT Cells and Enhances Their Effector Functions for Adoptive Immunotherapy
- (2018) Ho Ngai et al. JOURNAL OF IMMUNOLOGY
- Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting
- (2017) Julie R. Park et al. JOURNAL OF CLINICAL ONCOLOGY
- Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial
- (2017) Rajen Mody et al. LANCET ONCOLOGY
- CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma
- (2017) Andras Heczey et al. MOLECULAR THERAPY
- CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo
- (2016) Gengwen Tian et al. JOURNAL OF CLINICAL INVESTIGATION
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
- (2015) Adrienne H Long et al. NATURE MEDICINE
- Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15
- (2014) Y. Xu et al. BLOOD
- Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy
- (2014) A. Heczey et al. BLOOD
- Serial Transfer of Single-Cell-Derived Immunocompetence Reveals Stemness of CD8+ Central Memory T Cells
- (2014) Patricia Graef et al. IMMUNITY
- Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
- (2013) L. B. John et al. CLINICAL CANCER RESEARCH
- Design and development of therapies using chimeric antigen receptor-expressing T cells
- (2013) Gianpietro Dotti et al. IMMUNOLOGICAL REVIEWS
- Iodine-123 Metaiodobenzylguanidine Scintigraphy Scoring Allows Prediction of Outcome in Patients With Stage 4 Neuroblastoma: Results of the Cologne Interscore Comparison Study
- (2013) Boris Decarolis et al. JOURNAL OF CLINICAL ONCOLOGY
- IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity
- (2012) Daofeng Liu et al. JOURNAL OF CLINICAL INVESTIGATION
- Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
- (2011) C. U. Louis et al. BLOOD
- Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer
- (2011) Shinichiro Motohashi et al. CLINICAL IMMUNOLOGY
- A human memory T cell subset with stem cell–like properties
- (2011) Luca Gattinoni et al. NATURE MEDICINE
- Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy
- (2010) Kazuki Yamasaki et al. CLINICAL IMMUNOLOGY
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
- (2010) Alice L. Yu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages
- (2009) Liping Song et al. JOURNAL OF CLINICAL INVESTIGATION
- A Phase I-II Study of -Galactosylceramide-Pulsed IL-2/GM-CSF-Cultured Peripheral Blood Mononuclear Cells in Patients with Advanced and Recurrent Non-Small Cell Lung Cancer
- (2009) S. Motohashi et al. JOURNAL OF IMMUNOLOGY
- Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
- (2008) Mark E. Dudley et al. JOURNAL OF CLINICAL ONCOLOGY
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
- (2008) Martin A Pule et al. NATURE MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More